Literature DB >> 7128832

Possible functions of short-chain and medium-chain carnitine acyltransferases.

L L Bieber, R Emaus, K Valkner, S Farrell.   

Abstract

Several mammalian tissue contain water-soluble, branched chain acylcarnitines and other short-chain aliphatic acylcarnitines and also contain a broad spectrum of short-chain and medium-chain carnitine acyltransferase (CAT) activities. Although carnitine can stimulate the oxidation of branched chain alpha-ketoacids, it has not been established that carnitine is required for the oxidation of the alpha-ketoacids in the matrix of mitochondria. Rather it probably acts as a reversible sink for acyl residues, thereby generating CoASH, which can be used to maintain normal metabolism; thus carnitine would have a facilitative rather than an obligatory role. Microsomes and peroxisomes contain medium- and short-chain CATs. This occurrence is short- and medium-chain CATs in peroxisomes is consistent with carnitine's being involved in shuttling the chain-shortened products of beta-oxidation out of peroxisomes. Human urine contains a spectrum of short-chain acylcarnitines and data are presented that show a large amount of propionylcarnitine in the urine of the individual with a metabolic problem. The cumulative data are consistent with the conclusion that carnitine has multiple roles in mammalian metabolism, including the shuttling of beta-oxidation chain-shortened products out of peroxisomes in liver, the modulation of the acyl-CoA/CoASH ratio in mammalian cells, and the translocation of acetyl units for selective synthesis in a yeast.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128832

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  24 in total

Review 1.  Current research in the organic acidurias.

Authors:  R A Chalmers
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 2.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

3.  Comparison of the active sites of the purified carnitine acyltransferases from peroxisomes and mitochondria by using a reaction-intermediate analogue.

Authors:  N Nic a' Bháird; G Kumaravel; R D Gandour; M J Krueger; R R Ramsay
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

4.  Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions.

Authors:  R Friolet; H Hoppeler; S Krähenbühl
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

5.  The effect of carnitine on Arabidopsis development and recovery in salt stress conditions.

Authors:  Aurélie Charrier; Sonia Rippa; Agnès Yu; Phuong-Jean Nguyen; Jean-Pierre Renou; Yolande Perrin
Journal:  Planta       Date:  2011-08-19       Impact factor: 4.116

6.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

7.  L-propionyl-carnitine protects tissues from ischaemic injury in an 'in vivo' human ischaemia-reperfusion model.

Authors:  Giuseppe Maria Andreozzi; Romeo Martini; Rosa Maria Cordova; Alessandra D'Eri
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

8.  Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.

Authors:  Antonio Strano
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

9.  Effects of combined treatment with simvastatin and L-carnitine on triglyceride levels in diabetic patients with hyperlipidaemia.

Authors:  Francesco Brescia; Elisabetta Balestra; Maria Grazia Iasella; Aurelia Bellomo Damato
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

10.  Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects.

Authors:  P Harper; C E Elwin; G Cederblad
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.